X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs TTK HEALTHCARE - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. TTK HEALTHCARE FRESENIUS KABI ONCO./
TTK HEALTHCARE
 
P/E (TTM) x 22.1 27.6 80.1% View Chart
P/BV x 3.1 6.1 51.0% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 FRESENIUS KABI ONCO.   TTK HEALTHCARE
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
TTK HEALTHCARE
Mar-14
FRESENIUS KABI ONCO./
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs176663 26.5%   
Low Rs79399 19.7%   
Sales per share (Unadj.) Rs37.7535.6 7.0%  
Earnings per share (Unadj.) Rs5.115.9 31.9%  
Cash flow per share (Unadj.) Rs6.720.0 33.6%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.5137.6 30.9%  
Shares outstanding (eoy) m158.237.77 2,036.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.0 340.5%   
Avg P/E ratio x25.033.3 75.0%  
P/CF ratio (eoy) x18.926.5 71.4%  
Price / Book Value ratio x3.03.9 77.5%  
Dividend payout %025.1 0.0%   
Avg Mkt Cap Rs m20,1354,127 487.8%   
No. of employees `0001.21.7 67.4%   
Total wages/salary Rs m703607 115.9%   
Avg. sales/employee Rs Th5,176.22,436.7 212.4%   
Avg. wages/employee Rs Th610.4355.2 171.9%   
Avg. net profit/employee Rs Th699.672.5 964.4%   
INCOME DATA
Net Sales Rs m5,9634,162 143.3%  
Other income Rs m1861 29.4%   
Total revenues Rs m5,9814,223 141.6%   
Gross profit Rs m1,430197 725.6%  
Depreciation Rs m25832 813.6%   
Interest Rs m-2630 -87.0%   
Profit before tax Rs m1,216197 618.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m34273 470.1%   
Profit after tax Rs m806124 650.4%  
Gross profit margin %24.04.7 506.4%  
Effective tax rate %28.137.0 76.0%   
Net profit margin %13.53.0 454.0%  
BALANCE SHEET DATA
Current assets Rs m5,1021,629 313.2%   
Current liabilities Rs m2,3851,058 225.5%   
Net working cap to sales %45.613.7 332.1%  
Current ratio x2.11.5 138.9%  
Inventory Days Days15030 503.9%  
Debtors Days Days11334 337.3%  
Net fixed assets Rs m5,148556 925.4%   
Share capital Rs m15878 203.6%   
"Free" reserves Rs m6,556878 746.4%   
Net worth Rs m6,7321,069 629.6%   
Long term debt Rs m952159 600.0%   
Total assets Rs m10,3882,399 432.9%  
Interest coverage x-45.87.6 -604.0%   
Debt to equity ratio x0.10.1 95.3%  
Sales to assets ratio x0.61.7 33.1%   
Return on assets %7.56.4 117.1%  
Return on equity %12.011.6 103.3%  
Return on capital %14.618.5 79.1%  
Exports to sales %74.50.8 9,420.2%   
Imports to sales %24.81.4 1,768.7%   
Exports (fob) Rs m4,44133 13,497.3%   
Imports (cif) Rs m1,47758 2,534.1%   
Fx inflow Rs m5,29833 16,102.1%   
Fx outflow Rs m1,77263 2,804.6%   
Net fx Rs m3,525-30 -11,638.8%   
CASH FLOW
From Operations Rs m1,274127 1,006.4%  
From Investments Rs m-1,204-146 824.8%  
From Financial Activity Rs m-19622 -895.4%  
Net Cashflow Rs m-1263 -5,052.0%  

Share Holding

Indian Promoters % 0.0 65.4 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 3.7 8.1%  
FIIs % 9.6 5.2 184.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 25.8 35.3%  
Shareholders   42,599 12,723 334.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT LTD.  ABBOTT INDIA  PLETHICO PHARMA  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 43.1%

Jun 14, 2018 | Updated on Jun 14, 2018

For the quarter ended March 2018, TTK HEALTHCARE has posted a net profit of Rs 80 m (up 43.1% YoY). Sales on the other hand came in at Rs 1 bn (up 21.4% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - DISHMAN PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS